정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1234 | Withdrawn | Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults | COVID-19 | Biological: candidate vaccine, SCB-2020S | Phase 2 | Clover Biopharmaceuticals AUS Pty Ltd | INDUSTRY | 0 | All | 18 Years | |
| 1233 | Recruiting | Immunogenicity and Safety of an Inactivated COVID-19 Vaccine | COVID-19 | Biological: Inactivated COVID-19 Vaccine Biological: 23-valent pneumococcal polysaccharide vaccine Biological: Inactivated Hepatitis A Vaccine |
Phase 4 | Sinovac Research and Development Co., Ltd. | INDUSTRY | 270 | All | 18 Years | Rushan City Center for Disease Control and Prevention, Weihai, Shandong, China |
| 1232 | Recruiting | Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD | COPD | Biological: Inactivated COVID-19 vaccine | Phase 4 | China National Biotec Group Company Limited, Zhejiang Provincial Center for Disease Control and Prevention, Beijing Institute of Biological Products Co Ltd. | INDUSTRY | 400 | All | 60 Years | Zhejiang provincial center for disease control and prevention, Hangzhou, Zhejiang, China |
| 1231 | Recruiting | Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD | Copd | Biological: Inactivated COVID-19 vaccine | Phase 4 | China National Biotec Group Company Limited, Hubei Provincial Center for Disease Control and Prevention, Wuhan Institute of Biological Products Co., Ltd | INDUSTRY | 400 | All | 60 Years | Hubei Center for Disease Control and Prevention, Wuhan, Hubei, China |
| 1230 | Recruiting | Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected | COVID-19 | Biological: Inactivated COVID-19 vaccine | Phase 4 | China National Biotec Group Company Limited, Hubei Provincial Center for Disease Control and Prevention, Wuhan Institute of Biological Products Co., Ltd | INDUSTRY | 400 | All | 18 Years | Hubei Center for Disease Control and Prevention, Wuhan, Hubei, China |
| 1229 | Recruiting | Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected | HIV Infections | Biological: Inactivated COVID-19 vaccine | Phase 4 | China National Biotec Group Company Limited, Zhejiang Provincial Center for Disease Control and Prevention, Beijing Institute of Biological Products Co Ltd. | INDUSTRY | 400 | All | 18 Years | Zhejiang provincial center for disease control and prevention, Hangzhou, Zhejiang, China |
| 1228 | Not yet recruiting | Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children | Bordetella Pertussis, Whooping Cough | Biological: BPZE1 pertussis vaccine and placebo Biological: BPZE1 pertussis vaccine and Boostrix Biological: Placebo and Boostrix |
Phase 2 | ILiAD Biotechnologies | INDUSTRY | 600 | All | 6 Years ~ 16 Years | Birmingham Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom Bradford Royal Infirmary, Bradford, United Kingdom Bristol Royal Hospital For Children, Bristol, United Kingdom Addenbrooke's Hospital, Cambridge, United Kingdom Cardiff Royal Infirmary - PPDS, Cardiff, United Kingdom Leicester Children's Hospital, Ward 14, Level 4,, Leicester, United Kingdom Alder Hey Childrens Hospital, Liverpool, United Kingdom St George's Healthcare NHS Trust, London, United Kingdom St Mary's Hospital - PPDS, London, United Kingdom Royal Manchester Children's Hospital - PPDS, Manchester, United Kingdom Centre for Clinical Vaccinology and Tropical Medic, Oxford, United Kingdom University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom |